<DOC>
	<DOCNO>NCT00307645</DOCNO>
	<brief_summary>The aim IMPROVE define optimal maintenance therapy ANCA-associated vasculitides ( AASV ) compare AZA ( standard regimen ) MMF term efficacy , i.e . prevent relapse . HYPOTHESIS : MMF might effective azathioprine maintenance drug AASV patient , reduce 50 % relapse rate , frequency adverse effect</brief_summary>
	<brief_title>IMPROVE : Mycophenolate Mofetil Versus Azathioprine Maintenance Therapy ANCA Associated Systemic Vasculitis</brief_title>
	<detailed_description>AASV , include Wegener â€™ granulomatosis ( WG ) microscopic polyangiitis ( MPA ) renal limited vasculitis ( RLV ) , progressive , multisystem , autoimmune disease require prescription immunosuppressive therapy . Treatment use corticosteroid cytotoxic drug standardise ( ECSYSVASTRIAL project ) , relapse rate remain high treatment-related toxicity non negligible . The IMPROVE trial aim reduce relapse rate use mycophenolate mofetil ( MMF ) maintenance therapy . The potential benefit MMF suggest publish open uncontrolled study . Patients newly diagnose systemic AASV randomly assign receive either MMF reference treatment azathioprine ( AZA ) , remission obtain cyclophosphamide prednisone . MMF AZA continue total 42 month therapy concomitant prednisone dose taper . The study last 48 month . Hence , within last 6 month study duration , patient receive immunosuppressive drug . The primary end-point disease-free period , take period time remission relapse study end ; secondary end-points adverse event , cumulative damage ( assess use damage score VDI ) immunosuppressive drug cumulative dose .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Newly diagnose patient WG , MPA renallimited vasculitis . ANCA positivity . ANCA positivity require PR3ANCA typical cANCA pattern indirect immunofluorescence ( IIF ) , preferably confirm antiPR3 ELISA . MPOANCA determine ELISA require demonstration pANCA , pANCA IIF require confirmation antiMPO ELISA . Optionally , central review ANCA serology perform . Age 18 75 year Any cytotoxic drug within previous year , unless start within one month entry accord protocol design Coexistence another systemic autoimmune disease , e.g . SLE Hepatitis B Hepatitis C infection HIV positivity Failure achieve remission 6 month CYC therapy Failure control progressive disease induction protocol Malignancy ( usually exclude unless agree trial coordinator ) Pregnancy inadequate contraception Age 18 75 years* Endstage renal failure unless active extrarenal disease require treatment ( temporal dependency hemodialysis exclusion criterion ) Inability inform consent After discussion trial administrator , patient le 18 year may incorporate separate application accord appropriate local ethic committee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>ANCA associate systemic vasculitis</keyword>
	<keyword>Maintenance therapy</keyword>
	<keyword>Azathioprine</keyword>
	<keyword>Mycophenolate mofetil</keyword>
</DOC>